BBH news

VanEck Biotech · Biotechnology · United States

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
15.2% of BBH
Investing.com · 28 Oct 2026, 02:41 UTC
+67%, +48%, +39%: our AI called these blue-chip breakouts and still holds them By Investing.com
15.2% of BBH
Medscape · 28 Oct 2026, 00:00 UTC
FDA Warns Amgen Over Cancer Drug Promotional Video
15.2% of BBH
Nature · 28 Oct 2026, 00:00 UTC
A human erythropoietin-albumin fusion protein tailored for enhanced plasma half-life and delivery across mucosal surfaces
15.2% of BBH
Where to buy BBH
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
firstwordpharma.com · 27 Oct 2026, 18:18 UTC
KOL Views Preview: What does Amgen's big Imdelltra win in 1L maintenance mean for future of SCLC?
15.2% of BBH
Market Screener · 27 Oct 2026, 22:30 UTC
Gilead Sciences Inc Announces National Agreement for LYVDELZI Seladelpar for Primary Biliary Cholangitis in Canada
12.8% of BBH
Where to buy BBH
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Investing.com · 27 Oct 2026, 14:26 UTC
Amgen stock may move 4.3% on earnings release next week By Investing.com
15.2% of BBH
Seeking Alpha · 27 Oct 2026, 12:22 UTC
Amgen Stock: A Biotech Bargain Heading Into Q3 Earnings (NASDAQ:AMGN) | Seeking Alpha
15.2% of BBH
RTTNews · 27 Oct 2026, 13:36 UTC
Gilead Reaches Canadian Reimbursement Deal For Liver Disease Drug Lyvdelzi
12.8% of BBH
Seeking Alpha · 28 Oct 2026, 11:43 UTC
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued (NASDAQ:REGN) | Seeking Alpha
6.2% of BBH
24/7 Wall St. · 28 Oct 2026, 16:04 UTC
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
5.3% of BBH
Markets Insider · 26 Oct 2026, 23:00 UTC
Amgen names David Gibbs to board of directors
15.2% of BBH
Investing.com · 26 Oct 2026, 21:56 UTC
Amgen appoints former Yum! Brands CEO to board of directors By Investing.com
15.2% of BBH
The Motley Fool · 26 Oct 2026, 11:30 UTC
Breakfast News: Science Strikes Back at Cancer
18.6% of BBH
Seeking Alpha · 28 Oct 2026, 20:02 UTC
Biogen anticipates $250M of run rate synergies by end of 2027 as it raises 2026 non-GAAP EPS to $12.20-$13 (NASDAQ:BIIB) | Seeking Alpha
3.6% of BBH
Seeking Alpha · 28 Oct 2026, 20:00 UTC
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript | Seeking Alpha
3.6% of BBH
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-10-28 | Seeking Alpha
3.6% of BBH
The Wall Street Journal · 27 Oct 2026, 10:05 UTC
The Biotech Leader Who Erased Team Lanes
9.1% of BBH
The Wall Street Journal · 28 Oct 2026, 20:17 UTC
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
3.4% of BBH
24/7 Wall St. · 26 Oct 2026, 22:00 UTC
Gilead Sciences Reaches $158.69, Its Second 52-Week High in Two Weeks
12.8% of BBH

BBH news

Where to buy BBH

Where to buy BBH